[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335168-105":59,"doc-detail-335168-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lexicon-for-blood-based-early-detection-and-screening-bloodpac-consensus-document","Lexicon for blood-based early detection and screening: BLOODPAC consensus document","","In the United States, 2.0 million new cancer cases and around 600,000 cancer deaths are estimated for 2024. Early detection improves the chance of successful treatment, yet population screening covers only a limited set of cancers, leaving many types unscreened. Novel non-invasive blood-based single- and multi-cancer detection tests (SCD and MCD) aim to identify cancer signals before symptoms or clinical diagnosis. The BLOODPAC ED&S Working Group compiled a lexicon to harmonize definitions, reduce communication barriers, and support FDA-informed adoption.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lexicon-for-blood-based-early-detection-and-screening-bloodpac-consensus-document/335168/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lexicon-for-blood-based-early-detection-and-screening-bloodpac-consensus-document/335168.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early cancer detection important in the BLOODPAC consensus document?","Question",{"text":112,"@type":113},"Early detection offers cancer patients the best chance of treatment success by identifying signals before symptoms and/or clinical diagnosis. The document also addresses gaps caused by limited population screening coverage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are SCD and MCD tests according to the document?",{"text":117,"@type":113},"SCD (single-cancer detection) and MCD (multi-cancer detection) are non-invasive blood-based tests designed to detect cancer signals prior to symptoms or clinical diagnosis. They may use next-generation sequencing and machine learning to identify biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"What problem does the ED&S Working Group’s lexicon address?",{"text":121,"@type":113},"The document states that stakeholders used inconsistent terminology for key concepts, causing confusion. The lexicon was compiled to harmonize definitions and reduce communication barriers across diverse groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335168,1790138219,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10. 1111/cts.70016  \nPOSITION PAPER  \nLexicon for blood-based early detection and screening: BLOODPAC consensus document  \nChristina A. Clarke1 | Breeana L. Mitchell2 | Girish Putcha3 | Emma Alme4 |  \nPeter Bach5 | Jonathan P. Beer6 | Tomasz M. Beer7 | Michelle A. Beidelschies7 | Jody Hoyos8 | Eric Klein1 | Peter Kuhn9  | Nancy Krunic10 | Kathryn Lang11 | Jerry S. H. Lee9  | Dorys Lopez Ramos12  | David Morgenstern5  | Elissa Quinn13 | Victoria M. Raymond4 | Wendy S. Rubinstein14  | Stephanie A. Sanchez2  |  \nRyan Serra15 | Mark Stewart16  | Lauren C. Leiman12  \nCorrespondence  \nLauren C. Leiman, P.O. Box 6010, River Forest, IL 60305, USA.  \nEmail: [lauren@bloodpac.org](lauren@bloodpac.org)  \nAbstract  \nIn the United States, 2.0 million new cancer cases and around 600,000 cancer deaths are estimated to occur in 2024. Early detection gives cancer patients the best chance for treatment success. Currently, cancer screening in the general population is recommended for a limited set of cancers; as a result, most cancer types are not regularly screened. Thus, in recent years, we have seen a wave of novel, non-invasive, single- and multi-cancer detection tests (SCD and MCD), promising detection of cancer signals prior to the onset of symptoms and/or clinical diagnosis. To accelerate the development, access, and adoption of these tests, the Blood Profiling Atlas in Cancer (BLOODPAC) Consortium, a collaborative infrastructure for developing standards and best practices, established the Early Detection & Screening (ED&S) Working Group. The early detection space is in need of consensus around definitions for SCD and MCD tests that harmonize terminology across diverse stakeholders, thereby reducing communication barriersand ultimately advancing the discipline. To this end, the ED&S Working Group compiled a lexicon of terms, chosen based on perceived importance, frequency of use, lack of clarity, and unique challenges in the context of SCD and MCD tests. This lexicon was submitted to the FDA for their feedback, which was incorporated. In this work, we present the first installment of the lexicon, consisting of 14 primary terms, that will be part of an online dictionary and provide a foundation for future projects of BLOODPAC's ED&S Working Group.  \nCo-first Authors: Christina Clarke, Bree Mitchell and Girish Putcha. For affiliations refer to page 5.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.  \nINTRODUCTION  \nIn the United States alone, 2.0 million new cancer cases and over 600,000 cancer deaths are estimated to occur in 2024.1 With advancements in screening and treatment strategies, trends in the incidence and mortality rates of cancer have steadily declined over the years; however, this has slowed or even reversed for some cancer types in recent years.1 In the United States, screening in the general population is recommended for a limited number of more prevalent cancer types, such as colorectal,2 breast,3 lung,4 and cervical5 cancers. However, existing screening strategies for these cancer types have limitations. For example, mammography screening for breast cancer has a high false positive rate leading many patients to unnecessary follow-up procedures.6 Low-dose computed tomography (LDCT) screening for lung cancer has been plagued with accessibility7 issues. Both LDCT and colonoscopy suffer from low adherence due to the time-consuming and invasive nature of the procedures.8,9 Together these barriers mean that less than 100% of eligible cancers are being detected through screening. Moreover, most cancer types are not currently covered by screening recommend","cbCainvXYwyHp13V","https://ap.wps.com/l/cbCainvXYwyHp13V","pdf",192770,"English","# Introduction\n## Early cancer detection tests and the need for a standardized lexicon","[{\"question\":\"Why is early cancer detection important in the BLOODPAC consensus document?\",\"answer\":\"Early detection offers cancer patients the best chance of treatment success by identifying signals before symptoms and/or clinical diagnosis. The document also addresses gaps caused by limited population screening coverage.\"},{\"question\":\"What are SCD and MCD tests according to the document?\",\"answer\":\"SCD (single-cancer detection) and MCD (multi-cancer detection) are non-invasive blood-based tests designed to detect cancer signals prior to symptoms or clinical diagnosis. They may use next-generation sequencing and machine learning to identify biomarkers.\"},{\"question\":\"What problem does the ED\\u0026S Working Group’s lexicon address?\",\"answer\":\"The document states that stakeholders used inconsistent terminology for key concepts, causing confusion. The lexicon was compiled to harmonize definitions and reduce communication barriers across diverse groups.\"}]","Lexicon for blood-based early detection and screening: BLOODPAC consensus document | PDF",1790009879,18]